The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical studies carried out in recent years that aimed to evaluate the composition of the microbiota in patients with relapsing–remitting MS (RR-MS). We also report what is available in the literature regarding the effectiveness of fecal microbiota transplantation and the role of the diet in restoring the intestinal bacterial population. Studies report that patients with RR-MS have a microbiota that, compared with healthy controls, has higher amounts of Pedobacteria, Flavobacterium, Pseudomonas, Mycoplana, Acinetobacter, Eggerthella, Dorea, Blautia, Streptococcus and Akkermansia. In contrast, MS patients have a microbiota with impoverished microbial populations of Prevotella, Bacteroides, Parabacteroides, Haemophilus, Sutterella, Adlercreutzia, Coprobacillus, Lactobacillus, Clostridium, Anaerostipes and Faecalibacterium. In conclusion, the restoration of the microbial population in patients with RR-MS appears to reduce inflammatory events and the reactivation of the immune system.

[1]  T. Yamamura,et al.  Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis , 2019, Brain : a journal of neurology.

[2]  G. Weinstock,et al.  Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota. , 2018, Cell metabolism.

[3]  David H. Miller,et al.  Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop , 2018, Multiple sclerosis.

[4]  X. Montalban,et al.  Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. , 2017, Autoimmunity reviews.

[5]  A. Mangalam,et al.  Gut microbiome in multiple sclerosis: The players involved and the roles they play , 2017, Gut microbes.

[6]  V. Martinelli,et al.  High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis , 2017, Science Advances.

[7]  C. Surawicz,et al.  Fecal Microbiota Transplantation. , 2017, Gastroenterology clinics of North America.

[8]  J. Machan,et al.  Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection , 2016, Annals of Internal Medicine.

[9]  Tingting Zhang,et al.  Excess Body Weight during Childhood and Adolescence Is Associated with the Risk of Multiple Sclerosis: A Meta-Analysis , 2016, Neuroepidemiology.

[10]  Justine W. Debelius,et al.  Gut dysbiosis is a feature of MS and it is characterized by bacteria able to regulate lymphocyte differentiation in vitro , 2016 .

[11]  Bangmao Wang,et al.  Systematic Review: Adverse Events of Fecal Microbiota Transplantation , 2016, PloS one.

[12]  Laura M Cox,et al.  Alterations of the human gut microbiome in multiple sclerosis , 2016, Nature Communications.

[13]  Krishna R. Kalari,et al.  Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls , 2016, Scientific Reports.

[14]  E. Waubant,et al.  Gut microbiota composition and relapse risk in pediatric MS: A pilot study , 2016, Journal of the Neurological Sciences.

[15]  Young-Seok Cho,et al.  Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives , 2016, Clinical endoscopy.

[16]  P. Vitaglione,et al.  Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study , 2016, Experimental biology and medicine.

[17]  R. Gold,et al.  Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. , 2015, Immunity.

[18]  M. Hattori,et al.  Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters , 2015, PloS one.

[19]  Manuel A. Friese,et al.  Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.

[20]  A. Venkatesan,et al.  Gut Microbiota in Multiple Sclerosis , 2015, Journal of Investigative Medicine.

[21]  N. Arbour,et al.  Multiple Sclerosis and T Lymphocytes: An Entangled Story , 2015, Journal of Neuroimmune Pharmacology.

[22]  T. Wilt,et al.  Fecal Microbiota Transplantation for Clostridium difficile Infection , 2015, Annals of Internal Medicine.

[23]  Xiaocang Cao,et al.  Fecal microbiota transplantation broadening its application beyond intestinal disorders. , 2015, World journal of gastroenterology.

[24]  M. Holick Vitamin D and brain health: the need for vitamin D supplementation and sensible sun exposure , 2015, Journal of internal medicine.

[25]  M. Carrithers Update on disease-modifying treatments for multiple sclerosis. , 2014, Clinical therapeutics.

[26]  D. Rubin,et al.  Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Journal of Crohn's & colitis.

[27]  K. Berer,et al.  Microbial view of central nervous system autoimmunity , 2014, FEBS letters.

[28]  G. Russell,et al.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. , 2014, JAMA.

[29]  P. Bhargava,et al.  The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. , 2014, Contemporary clinical trials.

[30]  P. Bhargava,et al.  Gut Microbiome and Multiple Sclerosis , 2014, Current Neurology and Neuroscience Reports.

[31]  D. Jarrossay,et al.  The Oral Commensal Streptococcus mitis Shows a Mixed Memory Th Cell Signature That Is Similar to and Cross-Reactive with Streptococcus pneumoniae , 2014, PloS one.

[32]  M. Hattori,et al.  Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. , 2014, Immunity.

[33]  R. Schmitz,et al.  The Intestinal Archaea Methanosphaera stadtmanae and Methanobrevibacter smithii Activate Human Dendritic Cells , 2014, PloS one.

[34]  M. Mellow,et al.  Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients , 2014, The American Journal of Gastroenterology.

[35]  D. Agrawal,et al.  Vitamin D and inflammatory diseases , 2014, Journal of inflammation research.

[36]  A. Bar-Or,et al.  Teriflunomide and Its Mechanism of Action in Multiple Sclerosis , 2014, Drugs.

[37]  L. Steinman Immunology of relapse and remission in multiple sclerosis. , 2014, Annual review of immunology.

[38]  J. Oksenberg Decoding multiple sclerosis: an update on genomics and future directions , 2013, Expert review of neurotherapeutics.

[39]  A. Ascherio Environmental factors in multiple sclerosis , 2013, Expert review of neurotherapeutics.

[40]  A. Rudensky,et al.  Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation , 2013, Nature.

[41]  M. Tomita,et al.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells , 2013, Nature.

[42]  Bing Xia,et al.  Increased Proportions of Bifidobacterium and the Lactobacillus Group and Loss of Butyrate-Producing Bacteria in Inflammatory Bowel Disease , 2013, Journal of Clinical Microbiology.

[43]  X. Yao,et al.  Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosis , 2013, Clinical & translational immunology.

[44]  N. Jantaratnotai,et al.  Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia. , 2013, International immunopharmacology.

[45]  R. Klopfleisch,et al.  Commensal Akkermansia muciniphila Exacerbates Gut Inflammation in Salmonella Typhimurium-Infected Gnotobiotic Mice , 2013, PloS one.

[46]  L. Brandt,et al.  An overview of fecal microbiota transplantation: techniques, indications, and outcomes. , 2013, Gastrointestinal endoscopy.

[47]  M. Hattori,et al.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.

[48]  I. Lavi,et al.  Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties , 2013, BMC Neurology.

[49]  Hanne F. Harbo,et al.  Sex and gender issues in multiple sclerosis , 2013, Therapeutic advances in neurological disorders.

[50]  Robert Weissert The Immune Pathogenesis of Multiple Sclerosis , 2013, Journal of Neuroimmune Pharmacology.

[51]  M. Vaisberg,et al.  Vitamin D3 Induces IDO+ Tolerogenic DCs and Enhances Treg, Reducing the Severity of EAE , 2013, CNS neuroscience & therapeutics.

[52]  K. Raza,et al.  Availability of 25-Hydroxyvitamin D3 to APCs Controls the Balance between Regulatory and Inflammatory T Cell Responses , 2012, The Journal of Immunology.

[53]  Casey T. Weaver,et al.  Reciprocal interactions of the intestinal microbiota and immune system , 2012, Nature.

[54]  K. Brown,et al.  Diet-Induced Dysbiosis of the Intestinal Microbiota and the Effects on Immunity and Disease , 2012, Nutrients.

[55]  J. H. Kim,et al.  Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis , 2012, Infection.

[56]  A. Macpherson,et al.  Interactions Between the Microbiota and the Immune System , 2012, Science.

[57]  A. Khoruts,et al.  Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection , 2012, The American Journal of Gastroenterology.

[58]  K. Rhodes,et al.  Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway , 2012, Journal of Pharmacology and Experimental Therapeutics.

[59]  Richard Hansen,et al.  IBD—what role do Proteobacteria play? , 2012, Nature Reviews Gastroenterology &Hepatology.

[60]  F. Paul,et al.  Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial , 2012, Trials.

[61]  F. Barkhof,et al.  Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial , 2011, Journal of the Neurological Sciences.

[62]  J. Bakken,et al.  Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[63]  Michelino Di Rosa,et al.  Vitamin D3: a helpful immuno‐modulator , 2011, Immunology.

[64]  W. D. de Vos,et al.  Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila , 2011, Front. Microbio..

[65]  F. Jadidi-Niaragh,et al.  Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis , 2011, Scandinavian journal of immunology.

[66]  L. Blizzard,et al.  Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[67]  K. Walsh,et al.  Adipokines in inflammation and metabolic disease , 2011, Nature Reviews Immunology.

[68]  K. Honda,et al.  Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species , 2011, Science.

[69]  N. Tubridy,et al.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis , 2010, Clinical and experimental immunology.

[70]  L. Brandt,et al.  Treatment of Refractory/Recurrent C. difficile-associated Disease by Donated Stool Transplanted Via Colonoscopy: A Case Series of 12 Patients , 2010, Journal of clinical gastroenterology.

[71]  A. Ascherio,et al.  Vitamin D and multiple sclerosis , 2010, The Lancet Neurology.

[72]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[73]  S. Dhib-jalbut,et al.  Interferon-β mechanisms of action in multiple sclerosis , 2010, Neurology.

[74]  A. Schwiertz,et al.  Microbiota and SCFA in Lean and Overweight Healthy Subjects , 2010, Obesity.

[75]  B. Roe,et al.  A core gut microbiome in obese and lean twins , 2008, Nature.

[76]  V. De Rosa,et al.  The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? , 2008, Journal of leukocyte biology.

[77]  L. Piccio,et al.  Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis , 2008, Journal of leukocyte biology.

[78]  R. Wilson,et al.  Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut , 2007, Proceedings of the National Academy of Sciences.

[79]  M. Hutchinson Natalizumab: A new treatment for relapsing remitting multiple sclerosis , 2007, Therapeutics and clinical risk management.

[80]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[81]  E. Frohman,et al.  Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.

[82]  V. De Rosa,et al.  Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Nitin J. Karandikar,et al.  High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. , 2004, Blood.

[84]  G. Matarese,et al.  The weight of leptin in immunity , 2004, Nature Reviews Immunology.

[85]  A. Aljada,et al.  Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. , 2003, Diabetes.

[86]  J. Bakken,et al.  Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  L. Brandt,et al.  Treatment of recurrent Clostridium difficile–associated diarrhea by administration of donated stool directly through a colonoscope , 2000, American Journal of Gastroenterology.

[88]  Stephen R. Bloom,et al.  Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression , 1998, Nature.

[89]  E. Ravussin,et al.  Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.

[90]  T. Ziemssen,et al.  Glatiramer acetate: mechanisms of action in multiple sclerosis. , 2007, International review of neurobiology.

[91]  M. Rovaris,et al.  Mitoxantrone for multiple sclerosis. , 2005, The Cochrane database of systematic reviews.